NextPoint Therapeutics, Inc.

NextPoint is launching a new world of precision therapeutics through its leading scientific work on the novel B7-H7/HHLA2 axis. Our team of proven drug developers is advancing an antibody-drug conjugate with our proprietary linker technology, a T-cell engager with wide therapeutic window, and a multi-functional checkpoint inhibitor. Our innovative approach integrates foundational science with a defined clinical biomarker to identify the right patient population for each B7-H7-directed modality, so that we can deliver first-in-class therapies to a broad range of cancer patients with B7-H7 upregulation including those who do not benefit from currently approved therapies such as PD-1/L1 inhibitors.